NEFL and Alzheimer disease: Moreover, the combination of plasma Aβ42, p-tau181, and NfL achieved an AUC of 0.79 (95% CI: 0.71-0.88, P = 2.77 × 10−7; Fig. 5) in discriminating mutation carriers from controls and significantly outperformed individual biomarkers (Supplementary Table 2), further supporting the predictive ability of these three plasma biomarkers for AD in Chinese populations.